血液系统恶性肿瘤的双靶向 CAR-T 细胞免疫治疗:2023 ASH 年会最新进展
Dual-targeted CAR T-cell immunotherapies for hematological malignancies: latest updates from the 2023 ASH annual meeting.
63.6分
★★★☆☆
站内排序·非疗效
ALL SOURCES
Dual-targeted CAR T-cell immunotherapies for hematological malignancies: latest updates from the 2023 ASH annual meeting.
Characteristics of tumor infiltrating lymphocytes in sinonasal mucosal melanoma and prognosis for patients.
共 2 条
MEMBER ACCOUNT
登录成功会直接打开下一页。